Following a full submission
AWMSG advice |
|||
| Status: Recommended | |||
Aripiprazole (Abilify Maintena®) 400 mg powder and solvent for prolonged released suspension for injection is recommended as an option for use within NHS Wales for the maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole. |
|||
|
|||
Medicine details |
|||
| Medicine name | aripiprazole monohydrate (Abilify Maintena®) | ||
| Formulation | 400 mg powder and solvent for prolonged-release suspension for injection | ||
| Reference number | 909 | ||
| Indication | Maintenance treatment of schizophrenia in adult patients stabilised with oral aripiprazole |
||
| Company | Otsuka Pharmaceutical (UK) Ltd | ||
| BNF chapter | Central nervous system | ||
| Submission type | Full | ||
| Status | Recommended | ||
| Advice number | 2214 | ||
| NMG meeting date | 18/06/2014 | ||
| AWMSG meeting date | 16/07/2014 | ||
| Ratification by Welsh Government | 13/08/2014 | ||
| Date of issue | 14/08/2014 | ||
| Date of last review | 29/09/2017 | ||